Research Report Details
Subscribe for industry reports
Author / Researcher : Global Markets Direct
Number Of Pages/Tabs : 67
Number Of Charts : N/A
Published Date : 04/27/2016
Industries : Multiple
Countries : All
Quality Score : 5
Have a question about this report?
24/7 Research Support
Talk to Zursh Analyst
+1 858 522 9998 or Email Us
The report provides comprehensive information on the therapeutics under development for Rosacea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Additionally, the report provides an overview of key players involved in therapeutic development for Rosacea and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications.
The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information.
Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Rosacea - The report reviews pipeline therapeutics for Rosacea by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Rosacea therapeutics and enlists all their major and minor projects - The report assesses Rosacea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Rosacea Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Rosacea - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Rosacea pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Rosacea Overview 7 Therapeutics Development 8 Pipeline Products for Rosacea - Overview 8 Rosacea - Therapeutics under Development by Companies 9 Rosacea - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Rosacea - Products under Development by Companies 13 Rosacea - Companies Involved in Therapeutics Development 14 Allergan Plc 14 Amorepacific Corporation 15 Delenex Therapeutics AG 16 Foamix Pharmaceuticals Ltd. 17 Hovione FarmaCiencia SA 18 Merz Pharma GmbH & Co. KgaA 19 Promius Pharma, LLC 20 TWi Pharmaceuticals, Inc. 21 Valeant Pharmaceuticals International, Inc. 22 Rosacea - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 AC-701 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 ACUD-1 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 DLX-1008 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 DMT-200 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 DMT-210 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 DMT-220 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 FMX-103 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 incobotulinumtoxin A - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 itraconazole - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 minocycline - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 omiganan pentahydrochloride - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 oxymetazoline hydrochloride - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 PAC-14028 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 PDI-320 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 tetracycline MR - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Rosacea - Recent Pipeline Updates 51 Rosacea - Dormant Projects 57 Rosacea - Discontinued Products 59 Rosacea - Product Development Milestones 60 Featured News & Press Releases 60 Oct 20, 2015: Foamix Announces Enrollment of First Patient in Phase 2 Clinical Trial of FMX103 in Papulopustular Rosacea 60 Apr 07, 2015: Dr. Reddy’s Laboratories and its subsidiary Promius Pharma announce the filing of NDA with the USFDA For DFD-09 60 Apr 17, 2014: Treatment for Facial Redness Associated With Rosacea Now Available in the UK 61 Feb 26, 2014: mirvaso the first and only treatment targeting the facial redness of rosacea approved by the european commission 61 Jan 29, 2014: Galderma Announces the Publication of Positive Results of the Long-Term Study of Mirvaso Gel for Treatment of Persistent Erythema of Rosacea 62 Dec 20, 2013: Galderma Receives CHMP Positive Opinion For Mirvaso 63 Sep 27, 2013: Galderma Announces Availability of Mirvaso (brimonidine) Topical Gel, 0.33% 63 Aug 26, 2013: Galderma Receives FDA Approval of Mirvaso 64 Jul 08, 2013: Signum Dermalogix Investigational New Drug Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea 65 Mar 16, 2012: Galderma Completes Phase III Trials Of Investigational Drug Targeting Facial Erythema Of Rosacea 65 Appendix 66 Methodology 66 Coverage 66 Secondary Research 66 Primary Research 66 Expert Panel Validation 66 Contact Us 66 Disclaimer 67 List of Tables Number of Products under Development for Rosacea, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Rosacea - Pipeline by Allergan Plc, H1 2016 14 Rosacea - Pipeline by Amorepacific Corporation, H1 2016 15 Rosacea - Pipeline by Delenex Therapeutics AG, H1 2016 16 Rosacea - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016 17 Rosacea - Pipeline by Hovione FarmaCiencia SA, H1 2016 18 Rosacea - Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2016 19 Rosacea - Pipeline by Promius Pharma, LLC, H1 2016 20 Rosacea - Pipeline by TWi Pharmaceuticals, Inc., H1 2016 21 Rosacea - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016 22 Assessment by Monotherapy Products, H1 2016 23 Number of Products by Stage and Target, H1 2016 25 Number of Products by Stage and Mechanism of Action, H1 2016 27 Number of Products by Stage and Route of Administration, H1 2016 29 Number of Products by Stage and Molecule Type, H1 2016 31 Rosacea Therapeutics - Recent Pipeline Updates, H1 2016 51 Rosacea - Dormant Projects, H1 2016 57 Rosacea - Dormant Projects (Contd..1), H1 2016 58 Rosacea - Discontinued Products, H1 2016 59 List of Figures Number of Products under Development for Rosacea, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Assessment by Monotherapy Products, H1 2016 23 Number of Products by Top 10 Targets, H1 2016 24 Number of Products by Stage and Top 10 Targets, H1 2016 24 Number of Products by Top 10 Mechanism of Actions, H1 2016 26 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 26 Number of Products by Routes of Administration, H1 2016 28 Number of Products by Stage and Routes of Administration, H1 2016 28 Number of Products by Molecule Types, H1 2016 30 Number of Products by Stage and Molecule Types, H1 2016 30
Summary of Source & MethodologyTrue
Global Markets Direct follows the highest standards when conducting primary and secondary research, including thousands of interviews with senior executives every year, to enable clients to make sound business decisions for their company in complete confidence. 1. 1 million-strong stakeholder group, plus 25,000 interviews annually 2. Rigorous checks on over 25,000 public and proprietary sources 3. Data modeled and forecasted with gold-standard methodology 4. Updated in real time 5. Expert insights and critical analysis from 700 experienced researchers and analysts If you would like to request the complete research methodology of this report or any additional information, please send us an email to email@example.com
Download additional documents & original sources used by researcher/publisher to support the report dataDownload Documents No documents available for download
Zursh quality control analysts have developed a nice rating algorithm to independently and objectively evaluate the quality of this report.